Abstract
Oncoproteins of the MYC family are major drivers of human tumorigenesis. Since a large body of evidence indicates that MYC proteins are transcription factors, studying their function has focused on the biology of their target genes. Detailed studies of MYC-dependent changes in RNA levels have provided contrasting models of the oncogenic activity of MYC proteins through either enhancing or repressing the expression of specific target genes, or as global amplifiers of transcription. In this Review, we first summarize the biochemistry of MYC proteins and what is known (or is unclear) about the MYC target genes. We then discuss recent progress in defining the interactomes of MYC and MYCN and how this information affects central concepts of MYC biology, focusing on mechanisms by which MYC proteins modulate transcription. MYC proteins promote transcription termination upon stalling of RNA polymerase II, and we propose that this mechanism enhances the stress resilience of basal transcription. Furthermore, MYC proteins coordinate transcription elongation with DNA replication and cell cycle progression. Finally, we argue that the mechanism by which MYC proteins regulate the transcription machinery is likely to promote tumorigenesis independently of global or relative changes in the expression of their target genes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dang, C. V. MYC on the path to cancer. Cell 149, 22–35 (2012).
Mateyak, M. K., Obaya, A. J., Adachi, S. & Sedivy, J. M. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8, 1039–1048 (1997).
Sansom, O. J. et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 446, 676–679 (2007).
Kawauchi, D. et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21, 168–180 (2012).
Vo, B. T. et al. The interaction of Myc with Miz1 defines medulloblastoma subgroup identity. Cancer Cell 29, 5–16 (2016).
Dammert, M. A. et al. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat. Commun. 10, 3485 (2019).
Makela, T. P., Saksela, K., Evan, G. & Alitalo, K. A fusion protein formed by L-myc and a novel gene in SCLC. EMBO J. 10, 1331–1335 (1991).
Nau, M. M. et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318, 69–73 (1985).
Gabay, M., Li, Y. & Felsher, D. W. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb. Perspect. Med. 4, a014241 (2014).
Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679–683 (2008).
Annibali, D. et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat. Commun. 5, 4632 (2014).
Dubois, N. C. et al. Placental rescue reveals a sole requirement for c-Myc in embryonic erythroblast survival and hematopoietic stem cell function. Development 135, 2455–2465 (2008).
Sodir, N. M. et al. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 25, 907–916 (2011).
Wu, C. H. et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl Acad. Sci. USA 104, 13028–13033 (2007).
Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227–231 (2016).
Kortlever, R. M. et al. Myc cooperates with ras by programming inflammation and immune suppression. Cell 171, 1301–1315.e14 (2017).
Topper, M. J. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171, 1284–1300 (2017).
Conacci-Sorrell, M., McFerrin, L. & Eisenman, R. N. An overview of MYC and its interactome. Cold Spring Harb. Perspect. Med. 4, a014357 (2014).
Guo, J. et al. Sequence specificity incompletely defines the genome-wide occupancy of Myc. Genome Biol. 15, 482 (2014).
Mathsyaraja, H. et al. Max deletion destabilizes MYC protein and abrogates Emicro-Myc lymphomagenesis. Genes Dev. 33, 1252–1264 (2019).
Hurlin, P. J. et al. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J. 22, 4584–4596 (2003).
Schaub, F. X. et al. Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas. Cell Syst. 6, 282–300.e2 (2018).
Walz, S. et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511, 483–487 (2014).
Farrell, A. S. & Sears, R. C. MYC degradation. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a014365 (2014).
Herold, S. et al. Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature 567, 545–549 (2019).
Welcker, M. et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl Acad. Sci. USA 101, 9085–9090 (2004).
Yeh, E. et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 6, 308–318 (2004).
Richards, M. W. et al. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proc. Natl Acad. Sci. USA 113, 13726–13731 (2016).
Dauch, D. et al. A MYC-Aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat. Med. 22, 744–753 (2016).
Zhang, N. et al. MYC interacts with the human STAGA coactivator complex via multivalent contacts with the GCN5 and TRRAP subunits. Biochim. Biophys. Acta 1839, 395–405 (2014).
McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D. & Cole, M. D. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94, 363–374 (1998).
Thomas, L. R. et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol. Cell 58, 440–452 (2015).
Kalkat, M. et al. MYC protein interactome profiling reveals functionally distinct regions that cooperate to drive tumorigenesis. Mol. Cell 72, 836–848.e7 (2018).
Thomas, L. R. et al. Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif. Oncogene 35, 3613–3618 (2016).
Nair, S. K. & Burley, S. K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112, 193–205 (2003).
Wei, Y. et al. Multiple direct interactions of TBP with the MYC oncoprotein. Nat. Struct. Mol. Biol. 26, 1035–1043 (2019).
Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K. & Sharp, P. A. A phase separation model for transcriptional control. Cell 169, 13–23 (2017).
Eilers, M. & Eisenman, R. N. Myc’s broad reach. Genes Dev. 22, 2755–2766 (2008).
Grandori, C. et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell Biol. 7, 311–318 (2005).
Gomez-Roman, N., Grandori, C., Eisenman, R. N. & White, R. J. Direct activation of RNA polymerase III transcription by c-Myc. Nature 421, 290–294 (2003).
Sabo, A. et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511, 488–492 (2014).
Eilers, M., Picard, D., Yamamoto, K. R. & Bishop, J. M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 340, 66–68 (1989).
Kress, T. R., Sabo, A. & Amati, B. MYC: connecting selective transcriptional control to global RNA production. Nat. Rev. Cancer 15, 593–607 (2015).
Muhar, M. et al. SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Science 360, 800–805 (2018).
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism and cancer. Cancer Discov. 5, 1024–1039 (2015).
Berwanger, B. et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2, 377–386 (2002).
Murphy, D. M. et al. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol. Carcinog. 50, 403–411 (2011).
Blanco-Bose, W. E. et al. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology 48, 1302–1311 (2008).
Yin, X. Y. et al. Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res. 61, 6487–6493 (2001).
Wanzel, M. et al. Akt and 14-3-3η regulate Miz1 to control cell-cycle arrest after DNA damage. Nat. Cell Biol. 7, 30–41 (2005).
Yustein, J. T. et al. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc. Natl Acad. Sci. USA 107, 3534–3539 (2010).
Seoane, J. et al. TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 3, 400–408 (2001).
Staller, P. et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 3, 392–399 (2001).
Herold, S. et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 10, 509–521 (2002).
Seoane, J., Le, H. V. & Massague, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729–734 (2002).
Wu, S. et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 22, 351–360 (2003).
Inghirami, G. et al. Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. Science 250, 682–686 (1990).
Gebhardt, A. et al. Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1. J. Cell Biol. 172, 139–149 (2006).
van Riggelen, J. et al. The interaction between Myc and Miz1 is required to antagonize TGFβ-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev. 24, 1281–1294 (2010).
Tu, W. B. et al. MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis. Cancer Cell 34, 579–595.e8 (2018).
Baluapuri, A. et al. MYC recruits SPT5 to RNA polymerase II to promote processive transcription elongation. Mol. Cell 74, 674–687.e11 (2019).
Kaur, M. & Cole, M. D. MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res. 73, 695–705 (2013).
Barna, M. et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456, 971–975 (2008).
Nilsson, J. A. et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7, 433–444 (2005).
Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67 (2012).
Nie, Z. et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68–79 (2012).
Fernandez, P. C. et al. Genomic targets of the human c-Myc protein. Genes Dev. 17, 1115–1129 (2003).
Lorenzin, F. et al. Different promoter affinities account for specificity in MYC-dependent gene regulation. eLife 5, e15161 (2016).
Gerlach, J. M. et al. PAF1 complex component Leo1 helps recruit Drosophila Myc to promoters. Proc. Natl Acad. Sci. USA 114, E9224–E9232 (2017).
Guccione, E. et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol. 8, 764–770 (2006).
Tesi, A. et al. An early Myc-dependent transcriptional program orchestrates cell growth during B-cell activation. EMBO Rep. 20, e47987 (2019).
Loven, J. et al. Revisiting global gene expression analysis. Cell 151, 476–482 (2012).
Huang, C. H. et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 28, 1800–1814 (2014).
Chipumuro, E. et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159, 1126–1139 (2014).
Lewis, L. M. et al. Replication study: transcriptional amplification in tumor cells with elevated c-Myc. eLife 7, e30274 (2018).
Wolf, E., Lin, C. Y., Eilers, M. & Levens, D. L. Taming of the beast: shaping Myc-dependent amplification. Trends Cell Biol. 25, 241–248 (2015).
Heidelberger, J. B. et al. Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. EMBO Rep. 19, e44754 (2018).
Besche, H. C., Haas, W., Gygi, S. P. & Goldberg, A. L. Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins. Biochemistry 48, 2538–2549 (2009).
von der Lehr, N. et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol. Cell 11, 1189–1200 (2003).
Dominguez-Sola, D. et al. Non-transcriptional control of DNA replication by c-Myc. Nature 448, 445–451 (2007).
Popov, N., Schulein, C., Jaenicke, L. A. & Eilers, M. Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover. Nat. Cell Biol. 12, 973–981 (2010).
Jacquet, K. et al. The TIP60 complex regulates bivalent chromatin recognition by 53BP1 through direct H4K20me binding and H2AK15 acetylation. Mol. Cell 62, 409–421 (2016).
Gorrini, C. et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448, 1063–1067 (2007).
Rahl, P. B. et al. c-Myc regulates transcriptional pause release. Cell 141, 432–445 (2010).
de Pretis, S. et al. Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation. Genome Res. 27, 1658–1664 (2017).
Buchel, G. et al. Association with aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle. Cell Rep. 21, 3483–3497 (2017).
Fong, N., Saldi, T., Sheridan, R. M., Cortazar, M. A. & Bentley, D. L. RNA Pol II dynamics modulate Co-transcriptional chromatin modification, CTD phosphorylation, and transcriptional direction. Mol. Cell 66, 546–557.e3 (2017).
Jaenicke, L. A. et al. Ubiquitin-dependent turnover of MYC antagonizes MYC/PAF1C complex accumulation to drive transcriptional elongation. Mol. Cell 61, 54–67 (2016).
Eberhardy, S. R. & Farnham, P. J. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J. Biol. Chem. 277, 40156–40162 (2002).
Dejure, F. R. et al. The MYC mRNA 3’-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels. EMBO J. 36, 1854–1868 (2017).
Crossley, M. P., Bocek, M. & Cimprich, K. A. R-loops as cellular regulators and genomic threats. Mol. Cell 73, 398–411 (2019).
Shivji, M. K. K., Renaudin, X., Williams, C. H. & Venkitaraman, A. R. BRCA2 regulates transcription elongation by RNA polymerase II to prevent R-loop accumulation. Cell Rep. 22, 1031–1039 (2018).
Salas-Armenteros, I. et al. Human THO-Sin3A interaction reveals new mechanisms to prevent R-loops that cause genome instability. EMBO J. 36, 3532–3547 (2017).
Kouzine, F. et al. Transcription-dependent dynamic supercoiling is a short-range genomic force. Nat. Struct. Mol. Biol. 20, 396–403 (2013).
Madabhushi, R. et al. Activity-induced DNA breaks govern the expression of neuronal early-response genes. Cell 161, 1592–1605 (2015).
Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 42, 668–675 (2010).
Gothe, H. J. et al. Spatial chromosome folding and active transcription drive DNA fragility and formation of oncogenic MLL translocations. Mol. Cell 75, 267–283.e12 (2019).
Hann, S. R., Thompson, C. B. & Eisenman, R. N. c-Myc oncogene protein synthesis is independent of the cell cycle in human and avian cells. Nature 314, 366–369 (1985).
Otto, T. et al. Stabilization of N-Myc is a critical function of Aurora a in human neuroblastoma. Cancer Cell 15, 67–78 (2009).
Topham, C. et al. MYC is a major determinant of mitotic cell fate. Cancer Cell 28, 129–140 (2015).
Xiao, D. et al. Polo-like kinase-1 regulates Myc stabilization and activates a feedforward circuit promoting tumor cell survival. Mol. Cell 64, 493–506 (2016).
Chakraborty, A. A. & Tansey, W. P. Inference of cell cycle-dependent proteolysis by laser scanning cytometry. Exp. Cell Res. 315, 1772–1778 (2009).
Hamperl, S. & Cimprich, K. A. Conflict Resolution in the genome: how transcription and replication make it work. Cell 167, 1455–1467 (2016).
Poli, J. et al. Mec1, INO80, and the PAF1 complex cooperate to limit transcription replication conflicts through RNAPII removal during replication stress. Genes Dev. 30, 337–354 (2016).
Ross, J. et al. Deletion of the Miz-1 POZ domain increases efficacy of cytarabine treatment in T- and B-ALL/Lymphoma mouse models. Cancer Res. 79, 4184–4195 (2019).
Kress, T. R. et al. Identification of MYC-dependent transcriptional programs in oncogene-addicted liver tumors. Cancer Res. 76, 3463–3472 (2016).
Bermejo, R. et al. The replication checkpoint protects fork stability by releasing transcribed genes from nuclear pores. Cell 146, 233–246 (2011).
Su, Y. et al. Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev. 32, 1398–1419 (2018).
Sjostrom, S. K., Finn, G., Hahn, W. C., Rowitch, D. H. & Kenney, A. M. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev. Cell 9, 327–338 (2005).
Brockmann, M. et al. Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-Myc in childhood neuroblastoma. Cancer Cell 24, 75–89 (2013).
Hydbring, P. et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc. Natl Acad. Sci. USA 107, 58–63 (2010).
Benassi, B. et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol. Cell 21, 509–519 (2006).
Tan, J. et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov. 3, 1156–1171 (2013).
Li, Q. & Dang, C. V. c-Myc overexpression uncouples DNA replication from mitosis. Mol. Cell Biol. 19, 5339–5351 (1999).
Goga, A., Yang, D., Tward, A. D., Morgan, D. O. & Bishop, J. M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13, 820–827 (2007).
Ricke, R. M., Jeganathan, K. B., Malureanu, L., Harrison, A. M. & van Deursen, J. M. Bub1 kinase activity drives error correction and mitotic checkpoint control but not tumor suppression. J. Cell Biol. 199, 931–949 (2012).
Kessler, J. D. et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348–353 (2012).
Chen, L. et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol. Cell 69, 412–425 (2018).
Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
Hsu, T. Y. T. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384–388 (2015).
Iwai, K. et al. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol. Med. 10, e8289 (2018).
Cossa, G. et al. Localized inhibition of protein phosphatase 1 by NUAK1 promotes spliceosome activity and reveals a MYC-sensitive feedback control of transcription. Mol. Cell (in the press) (2020).
Liu, L. et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 483, 608–612 (2012).
Zhang, W. et al. Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer. Clin. Cancer Res. 24, 696–707 (2018).
Goldenberg, O., Erez, E., Nimrod, G. & Ben-Tal, N. The ConSurf-DB: pre-calculated evolutionary conservation profiles of protein structures. Nucleic Acids Res. 37, D323–D327 (2009).
Acknowledgements
We thank several colleagues in the field for numerous fruitful discussions and apologize to the many colleagues whose work we did not quote due to lack of space. The work in the authors’ laboratories is funded by grants from the European Research Council (AuroMYC, TarMyc) and the German Research Council (DFG).
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Peer review information
Nature Reviews Molecular Cell biology thanks William Tansey and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Phospho-degron
-
A short amino acid motif that is recognized by a ubiquitin ligase and promotes the degradation of the protein. Ubiquitin ligases often recognize degrons upon phosphorylation of a critical residue, hence the term phospho-degron.
- Bio-ID techniques
-
Allow the systematic identification in living cells of proteins that are in close proximity to a protein of interest fused to a biotin ligase.
- Promoter-proximal pausing
-
A transcription regulatory step, whereby RNA polymerase II pauses about 80 nucleotides downstream of the transcription start site.
- R-loop
-
A three-stranded nucleic acid structure consisting of an RNA–DNA hybrid and the corresponding single strand of DNA.
- Replication–transcription conflicts
-
Collusions of the transcription and replication machineries during S phase, which could result in DNA damage and genome instability.
- Pattern recognition receptors
-
Cellular innate immunity factors that recognize molecules that are typical of pathogens.
Rights and permissions
About this article
Cite this article
Baluapuri, A., Wolf, E. & Eilers, M. Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol 21, 255–267 (2020). https://doi.org/10.1038/s41580-020-0215-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41580-020-0215-2
This article is cited by
-
The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer
Journal of Experimental & Clinical Cancer Research (2024)
-
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
Nature Communications (2024)
-
PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma
Nature Communications (2024)
-
AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis
Oncogene (2024)
-
Protein phosphatase 1 regulatory subunit 15 A promotes translation initiation and induces G2M phase arrest during cuproptosis in cancers
Cell Death & Disease (2024)